It is one of the most popular targets in the treatment of HCC in recent years, and there are several clinical traits that reported that GPC3 shows great potential to be an immunotherapeutic target for HCC (Ho and Kim, 2011; Zhu et al., 2013; Du et al., 2021). The gene discussed is GPC3; the disease is hepatocellular carcinoma.